EC 0225

Drug Profile

EC 0225

Alternative Names: DAVLBH and mitomycin-C conjugate; Desacetylvinblastine hydrazide and mitomycin-C conjugate; EC0225

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Drug conjugates; Vinca alkaloids
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Microtubule protein inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV, Injection)
  • 01 Nov 2010 Endocyte completes a phase I trial in metastatic Cancer in USA
  • 04 Jun 2010 Interim adverse events and efficacy data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top